Divalprid-OD Tablets contain Divalproex Sodium Extended Release 250 mg, 500 mg, or 750 mg. Divalproex sodium is an extended-release antiepileptic formulation that dissociates into valproate ions after oral administration to provide prolonged therapeutic plasma concentrations.

Divalprid-OD Tablets provide extended-release delivery for sustained seizure control with convenient once-daily dosing. The formulation is effective as both monotherapy and adjunctive therapy for complex partial seizures and is also indicated for the management of bipolar manic episodes and migraine prophylaxis. By increasing central nervous system gamma-aminobutyric acid (GABA) concentrations, it helps reduce neuronal excitability and prevent seizure activity.

Divalprid-OD Tablets are indicated as monotherapy and adjunctive therapy for the treatment of patients with complex partial seizures occurring either alone or in association with other seizure types. They are also indicated for the treatment of manic episodes associated with bipolar disorder and for the prophylaxis of migraine headaches in adults.

Divalproex sodium dissociates in the gastrointestinal tract to release the valproate ion, which is responsible for its pharmacological activity. Its antiepileptic effect is believed to result primarily from increasing the concentration of gamma-aminobutyric acid (GABA) within the brain, thereby enhancing inhibitory neurotransmission and reducing abnormal neuronal excitability. This mechanism contributes to effective seizure control and stabilization of neuronal activity.

For complex partial seizures, the recommended initial dose in adults and children aged 10 years and above is 10–15 mg/kg/day administered in divided doses, with gradual increases of 5–10 mg/kg/week as required, up to a maximum of 60 mg/kg/day. For manic episodes associated with bipolar disorder, the recommended initial dose is 25 mg/kg/day, which may be increased rapidly to achieve the desired clinical response, not exceeding 60 mg/kg/day. For migraine prophylaxis, the recommended adult dose is 500 mg once daily for one week, which may be increased to 1000 mg once daily, or as directed by the physician.

Divalprid-OD Tablets are contraindicated in patients with hepatic disease or significant hepatic dysfunction, urea cycle disorders, or known hypersensitivity to Divalproex Sodium or any component of the formulation.